An Indeterminate FNA Finding
Thyroid nodules are increasingly prevalent. Although 85% to 95% of thyroid nodules are benign,6,7 thyroid cancer is the most common endocrine cancer and ranks as the ninth most common cancer in the United States.2
Palpable thyroid nodules occur in 5% to 7% of the adult population, but only 5% to 15% of those are diagnosed as thyroid cancer. Fine needle aspiration (FNA) is currently the standard preoperative diagnostic procedure used to evaluate thyroid nodules for cancer risk.
Cytologic examination results are often indeterminate
- Up to 35% of FNA biopsy results are indeterminate.3
- Among patients with cytologically indeterminate biopsies, the risk of malignancy can vary widely between institutions.3,8
- ~66% of nodules obtained from diagnostic surgery (hemithyroidectomy) are benign.9
Molecular Testing After an Indeterminate FNA Can Add Clarity
- Molecular testing can improve risk assessment by identifying genetic alterations and/or changes in gene expression profiles associated with thyroid cancer.3,4
- Improved risk assessment can help minimize the need for unnecessary surgeries, including identification of those patients who would benefit from total thyroidectomy rather than lobectomy.3,4
Coming Soon: Molecular Testing-Based Cytology Smear Slides
Interpace Diagnostics will soon be offering molecular testing based-cytology smear slides.